<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Beckwith-Wiedemann syndrome
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Beckwith-Wiedemann syndrome
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Beckwith-Wiedemann syndrome
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Brian Chung Hon-Yin, MD, FCCMG
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Cheryl Shuman, MS, CGC
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sanaa Choufani, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosanna Weksberg, MD, PhD, FRCPC, FCCMG, FACMG
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Helen V Firth, DM, FRCP, FMedSci
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth TePas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 25, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H22939433">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Beckwith-Wiedemann syndrome (BWS; MIM #130650) is a pediatric overgrowth disorder involving a predisposition to tumor development [
         <a href="#rid1">
          1
         </a>
         ]. The clinical presentation is highly variable, and some cases lack the characteristic features originally described by Beckwith and Wiedemann [
         <a href="#rid2">
          2,3
         </a>
         ]. BWS exhibits etiologic molecular heterogeneity, and some molecular alterations correlate with specific phenotypic features of BWS.
        </p>
        <p>
         The epidemiology, genetics, pathogenesis, clinical manifestations, diagnosis, management, and prognosis of BWS are reviewed in this topic.
        </p>
        <p class="headingAnchor" id="H1618222">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         BWS is a panethnic disorder with an estimated population prevalence of 1 in 10,300 to 13,700 [
         <a href="#rid4">
          4,5
         </a>
         ]. This figure most likely represents an underestimate because milder phenotypes may not be ascertained. The prevalence is approximately equal in males and females, with the notable exception of an increased frequency of female versus male monozygotic twins [
         <a href="#rid6">
          6
         </a>
         ]. BWS usually occurs sporadically (85 percent), but familial transmission occurs in approximately 15 percent of cases. Subfertility and/or use of assisted reproductive technology (ART) is associated with an increased risk of imprinting disorders [
         <a href="#rid7">
          7
         </a>
         ], with a 10-fold increased risk of BWS seen in live births from ART compared with natural conception in one Italian study [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1618409">
         <span class="h1">
          GENETICS AND PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Generally, both the maternally and paternally inherited alleles of each autosomal gene pair are expressed. Approximately 100 genes across the genome are known to be imprinted, with many more predicted [
         <a href="#rid9">
          9
         </a>
         ]. Imprinted genes are expressed monoallelically in a parent of origin-specific manner  (
         <a class="graphic graphic_figure graphicRef54712" href="/z/d/graphic/54712.html" rel="external">
          figure 1
         </a>
         ). That is, for a given imprinted gene pair, one parental allele is exclusively or preferentially expressed, whereas the other allele is silenced or weakly expressed. Genomic imprinting is regulated by epigenetic mechanisms. These include noncoding RNAs and chemical modifications extrinsic to the primary nucleotide sequence, such as DNA methylation and histone protein tail modifications. Different DNA methylation and histone modification states underpin the expression or silencing of imprinted alleles. Thus, imprinted alleles demonstrate differential DNA methylation. Imprinted genes occur in clusters referred to as imprinted domains and are regulated
         <em>
          in
         </em>
         <em>
          cis
         </em>
         (on the same chromosome) by imprinting centers (ICs). ICs are comprised of differentially methylated regions (DMRs) of DNA. (See
         <a class="medical medical_review" href="/z/d/html/2897.html" rel="external">
          "Inheritance patterns of monogenic disorders (Mendelian and non-Mendelian)", section on 'Parent-of-origin effects (imprinting)'
         </a>
         .)
        </p>
        <p>
         Dysregulation of imprinted gene expression in the chromosome 11p15.5 region can result in the BWS phenotype [
         <a href="#rid10">
          10-12
         </a>
         ]. The critical BWS genes in that region include insulin-like growth factor 2 (
         <em>
          IGF2
         </em>
         ) and
         <em>
          H19
         </em>
         in domain 1 and cyclin-dependent kinase inhibitor 1C (
         <em>
          CDKN1C
         </em>
         ), potassium channel voltage-gated KQT-like subfamily member 1 (
         <em>
          KCNQ1
         </em>
         ), and
         <em>
          KCNQ1
         </em>
         -overlapping transcript 1 (
         <em>
          KCNQ1OT1
         </em>
         , or long QT intronic transcript 1) in domain 2. A chromosome 11p15 molecular alteration is identified in only approximately 80 percent of persons with BWS. This is due in part to somatic mosaicism for some of the molecular alterations.
        </p>
        <p>
         Several different mechanisms can lead to BWS via epigenetic and/or genetic alterations in the chromosome 11p15.5 imprinted domains. These modifications change the relative contributions
         <strong>
         </strong>
         of parental alleles [
         <a href="#rid10">
          10-12
         </a>
         ] and include parent of origin-specific duplications, translocations/inversions, microdeletions, microduplications, DNA methylation changes at IC1 or IC2, and uniparental disomy (UPD). IC1 and IC2 regulated expression of genes in domains 1 and 2, respectively. UPD refers to the presence of two homologous chromosomal regions from one parent and none from the other.
        </p>
        <p>
         The following molecular alterations on chromosome 11p15.5 can be detected in persons with BWS [
         <a href="#rid12">
          12,13
         </a>
         ] (the approximate percentages for each type of alteration are noted [
         <a href="#rid14">
          14-18
         </a>
         ]):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Loss of methylation at IC2 (50 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Paternal UPD 11 (20 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gain of methylation at IC1 (5 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pathogenic variants of
         <em>
          CDKN1C
         </em>
         (5 percent in sporadic cases)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Paternal duplication, maternal inversion, or translocation involving the p15.5 band of chromosome 11 (less than 1 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unknown/undetected alteration (20 percent)
        </p>
        <p>
        </p>
        <p>
         In a proportion of persons with BWS, DNA methylation changes are associated with genomic alterations (microdeletions or microduplications); these usually involve IC1 and only rarely IC2 [
         <a href="#rid15">
          15-17,19-21
         </a>
         ]. A de novo deletion of the maternal
         <em>
          IGF2
         </em>
         allele (domain 1) along with
         <em>
          KCNQ1OT1
         </em>
         and a significant portion of
         <em>
          KCNQ1
         </em>
         (domain 2) alleles was reported in association with loss of methylation at IC2 and a BWS phenotype [
         <a href="#rid22">
          22
         </a>
         ]. Genomic alterations with or without changes in methylation are important because of their heritability.
        </p>
        <p>
         Domain 1 of the chromosome 11p15.5 region is the telomeric imprinted domain that contains the imprinted genes
         <em>
          H19
         </em>
         and
         <em>
          IGF2
         </em>
         .
         <em>
          H19
         </em>
         is a nontranslated RNA that may function as a tumor suppressor gene.
         <em>
          IGF2
         </em>
         is a potent fetal growth factor.
         <em>
          IGF2
         </em>
         overexpression is considered to be a key determinant in the development of BWS.
         <em>
          H19
         </em>
         and
         <em>
          IGF2
         </em>
         are reciprocally expressed imprinted genes, with
         <em>
          H19
         </em>
         maternally expressed and
         <em>
          IGF2
         </em>
         paternally expressed. The expression of genes within this domain is regulated by an IC upstream of
         <em>
          H19
         </em>
         called IC1 (
         <em>
          H19/IGF2
         </em>
         :IG DMR). IC1 is normally methylated on the paternal allele and unmethylated on the maternal allele. Regulation of transcription is accomplished by binding of the zinc-finger insulator protein CCCTC-binding factor (
         <em>
          CTCF
         </em>
         ) to its consensus sequence within IC1.
         <em>
          CTCF
         </em>
         only binds to the unmethylated sequence (maternal allele) and modulates the interaction of downstream enhancers interacting with the
         <em>
          H19
         </em>
         and
         <em>
          IGF2
         </em>
         promoters [
         <a href="#rid23">
          23
         </a>
         ]. Approximately 20 percent of patients with BWS and isolated IC1 gain of methylation carry single nucleotide variants or microdeletions that affect the octamer-binding transcription factor 4 (OCT4) or sex-determining region Y (SRY) box 2 (SOX2) transcription factor binding sites [
         <a href="#rid24">
          24
         </a>
         ]. The phenotype depends upon both the parental origin of the genomic alteration and the involvement of transcription factor binding sites [
         <a href="#rid25">
          25
         </a>
         ]. Such novel genomic aberrations continue to be described in both imprinted domains on 11p15.5.
        </p>
        <p>
         Domain 2 is the centromeric imprinted domain that contains the imprinted genes
         <em>
          CDKN1C
         </em>
         ,
         <em>
          KCNQ1
         </em>
         , and
         <em>
          KCNQ1OT1
         </em>
         . Regulation of this domain is controlled by an imprinting center, IC2 (
         <em>
          KCNQ1OT1
         </em>
         :TSS DMR), located in intron 10 of the
         <em>
          KCNQ1
         </em>
         gene. IC2 is a differentially methylated region [
         <a href="#rid26">
          26
         </a>
         ] that contains the promoter for
         <em>
          KCNQ1OT1
         </em>
         , a noncoding RNA with regulatory function. In BWS, loss of methylation at IC2 results in biallelic expression of the normally paternally expressed
         <em>
          KCNQ1OT1
         </em>
         . Individuals with BWS and loss of methylation at IC2 have reduced
         <em>
          CDKN1C
         </em>
         expression [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         Epigenetic alterations that involve both IC1 and IC2 generally indicate paternal UPD for a chromosomal segment including the 11p15.5 region [
         <a href="#rid10">
          10,14
         </a>
         ]. Segmental UPD of chromosome 11 is thought to arise from a postzygotic somatic recombination event, and, therefore, a mosaic distribution of this molecular change is found in most cases.
        </p>
        <p>
         Genomic alterations may also span domains 1 and 2.
        </p>
        <p>
         In approximately 20 percent of persons with BWS, clinical testing indicates normal methylation at IC1 and IC2 and no genomic abnormality involving chromosome 11p15.5. The absence of a detectable finding may be due to somatic mosaicism (see
         <a class="local">
          'Genetic testing'
         </a>
         below), alterations that do not involve the 11p15.5 region, or molecular etiologies not yet determined.
        </p>
        <p>
         Genomic loci outside of the chromosome 11p15.5 region have also been implicated in the etiology of BWS [
         <a href="#rid28">
          28
         </a>
         ]. As an example, an infant with features of BWS was found to have a large chromosome 7 deletion [
         <a href="#rid29">
          29
         </a>
         ]. This deletion included the growth factor receptor-bound protein 10 gene (
         <em>
          GRB10
         </em>
         ), an imprinted gene that inhibits the growth-promoting activities of insulin and insulin-like growth factors 1 and 2 by binding to the receptors for these molecules (insulin receptor and insulin-like growth factor 1 receptor). Chromosome 18q deletions have also been reported in persons with some features of BWS and developmental delay [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         Approximately 25 percent of persons with BWS and with loss of methylation at IC2 exhibit errors at additional imprinted loci beyond chromosome 11p15.5 [
         <a href="#rid18">
          18
         </a>
         ]. This condition, known as multi-locus imprinting disturbance (MLID) [
         <a href="#rid31">
          31
         </a>
         ], occurs in females more frequently than males at a ratio of 4:1 [
         <a href="#rid32">
          32
         </a>
         ]. MLID was previously reported exclusively in association with epigenetic errors rather than with UPD and copy number variations (CNVs) [
         <a href="#rid33">
          33
         </a>
         ]. However, a patient with BWS who had IC2 loss of methylation and MLID was identified with paternal UPD for chromosome 20 [
         <a href="#rid34">
          34
         </a>
         ]. Although the etiology of MLID is unknown in most cases, a number of mothers in these families have been shown to harbor compound heterozygous pathogenic variants in maternal effect genes that impact proteins of the subcortical maternal complex (SCMC) in the oocyte. These genes are important for early embryonic development including epigenetic reprogramming of the zygote [
         <a href="#rid35">
          35
         </a>
         ]. The phenotypic expression of pathogenic variants in the SCMC genes, NLR family pyrin domain containing 2 (
         <em>
          NLRP2
         </em>
         )
         <em>
          , NLRP5, NLRP7
         </em>
         , and peptidyl arginine deiminase 6 (
         <em>
          PADI6
         </em>
         ),
         <em>
         </em>
         include reproductive failure and molar pregnancies. The phenotypic consequences of such pathogenic variants have been extended to include children with BWS and/or Russell-Silver syndrome (RSS) with MLID [
         <a href="#rid36">
          36-40
         </a>
         ]. In some cases of BWS with MLID, there are relevant clinical findings due to imprinting errors outside of chromosome 11p15 (eg, hyperglycemia or hypocalcemia in BWS cases with concomitant imprinting errors on chromosome 6 [transient neonatal diabetes mellitus (TNDM)] or chromosome 20 [pseudohypoparathyroidism (PHP-1b)], respectively) [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H130269">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The classic hallmark features of BWS include omphalocele (exomphalos), macroglossia, and macrosomia (gigantism) [
         <a href="#rid2">
          2,3
         </a>
         ].
        </p>
        <p>
         Findings variably associated with BWS include [
         <a href="#rid41">
          41
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Macrosomia (traditionally defined as height and weight &gt;97
         <sup>
          th
         </sup>
         percentile)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemihyperplasia (asymmetric overgrowth of one or more regions of the body due to an abnormality of cell proliferation, [ie, increased cell number]); also referred to as lateralized overgrowth  (
         <a class="graphic graphic_picture graphicRef66409" href="/z/d/graphic/66409.html" rel="external">
          picture 1
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Macroglossia  (
         <a class="graphic graphic_picture graphicRef80654" href="/z/d/graphic/80654.html" rel="external">
          picture 2
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Omphalocele/umbilical hernia/diastasis recti  (
         <a class="graphic graphic_figure graphicRef69049" href="/z/d/graphic/69049.html" rel="external">
          figure 2
         </a>
         and
         <a class="graphic graphic_picture graphicRef81489" href="/z/d/graphic/81489.html" rel="external">
          picture 3
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anterior linear ear lobe creases/posterior helical ear pits  (
         <a class="graphic graphic_picture graphicRef77586" href="/z/d/graphic/77586.html" rel="external">
          picture 4
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Visceromegaly involving one or more intraabdominal organs including liver, spleen, kidneys, adrenal glands, and pancreas
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Embryonal tumors (eg, Wilms tumor, hepatoblastoma, neuroblastoma, rhabdomyosarcoma) in childhood (see
         <a class="medical medical_review" href="/z/d/html/6249.html" rel="external">
          "Presentation, diagnosis, and staging of Wilms tumor"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7750.html" rel="external">
          "Rhabdomyosarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5187.html" rel="external">
          "Clinical presentation, diagnosis, and staging evaluation of neuroblastoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16348.html" rel="external">
          "Pathology of malignant liver tumors", section on 'Hepatoblastoma'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cytomegaly of the fetal adrenal cortex
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Kidney abnormalities including structural anomalies, nephromegaly, nephrocalcinosis, later development of medullary sponge kidney
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cleft palate (rare)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neonatal hypoglycemia (see
         <a class="medical medical_review" href="/z/d/html/5053.html" rel="external">
          "Pathogenesis, screening, and diagnosis of neonatal hypoglycemia"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Facial nevus simplex and other vascular malformations (see
         <a class="medical medical_review" href="/z/d/html/5789.html" rel="external">
          "Vascular lesions in the newborn"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Characteristic facies, including midface hypoplasia and infraorbital creases  (
         <a class="graphic graphic_picture graphicRef80654" href="/z/d/graphic/80654.html" rel="external">
          picture 2
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiomegaly/structural cardiac anomalies; cardiomyopathy (rare)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Advanced bone age
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Family history of BWS and/or maternal history of recurrent pregnancy loss or molar pregnancy
        </p>
        <p>
        </p>
        <p>
         Incidence figures for the specific individual clinical findings in BWS vary widely in published reports, probably representing different ascertainment biases. These and other clinical features are discussed in greater detail in the sections that follow.
        </p>
        <p class="headingAnchor" id="H1351639">
         <span class="h2">
          Prenatal and perinatal
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common features of BWS observed prenatally are macrosomia (90 percent) and polyhydramnios (50 percent) [
         <a href="#rid42">
          42,43
         </a>
         ]. When omphalocele is detected prenatally, BWS is diagnosed in over 35 percent of fetuses with isolated omphalocele and 5 percent with nonisolated omphalocele [
         <a href="#rid44">
          44
         </a>
         ]. Additionally, features of BWS such as macroglossia, kidney abnormalities, visceromegaly, and large for gestational age may be detected on fetal ultrasound in the second or third trimester [
         <a href="#rid45">
          45
         </a>
         ]. Fifty percent of infants with BWS are born preterm. The umbilical cord can be long, and the placenta can average almost twice the normal weight for gestational age. Manifestations of BWS have been observed in approximately 17 to 25 percent of fetuses/liveborn infants from pregnancies complicated by placental mesenchymal dysplasia, which is distinctive cystic placental phenotype [
         <a href="#rid46">
          46-48
         </a>
         ]. Additional prenatal maternal complications may include diabetes mellitus, gestational hypertension, and/or proteinuria [
         <a href="#rid49">
          49
         </a>
         ], which may be associated with preeclampsia.
        </p>
        <p class="headingAnchor" id="H1351646">
         <span class="h2">
          Growth
         </span>
         <span class="headingEndMark">
          —
         </span>
         Macroglossia and macrosomia are generally present at birth, although postnatal onset of each of these features is sometimes observed [
         <a href="#rid50">
          50,51
         </a>
         ]. Adult height typically remains at the upper range of normal despite rapid growth in early childhood. The growth rate usually slows around age seven to eight years of age.
        </p>
        <p>
         When present, hemihyperplasia (also referred to as lateralized overgrowth or hemihypertrophy) is generally appreciated at birth but may become more or less evident as the child grows. Isolated lateralized overgrowth has been suggested as an alternate descriptor of this feature [
         <a href="#rid52">
          52
         </a>
         ]. Hemihyperplasia may affect segmental regions of the body and/or specific organs and tissues. When several segments are involved, hemihyperplasia may be limited to one side of the body (ipsilateral) or involve opposite sides of the body (contralateral) [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1351653">
         <span class="h2">
          Metabolic abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neonatal hypoglycemia is well documented [
         <a href="#rid4">
          4,54
         </a>
         ]. It poses a significant risk for developmental sequelae if severe and undetected or untreated. In those pregnancies deemed at increased risk for BWS either because of a positive family history or detection of fetal omphalocele on ultrasound, the newborn should be evaluated for hypoglycemia. Most cases of hypoglycemia are mild and transient; however, hypoglycemia can persist due to hyperinsulinism and be refractory to treatment. Delayed onset of hypoglycemia (ie, beyond the first two weeks of life) is also rarely observed.
        </p>
        <p>
         Other, less common endocrine/metabolic/hematologic findings include hypothyroidism, hypocalcemia, hyperlipidemia/hypercholesterolemia, and polycythemia [
         <a href="#rid54">
          54,55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1351660">
         <span class="h2">
          Structural anomalies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anterior abdominal wall defects, including omphalocele, umbilical hernia, and diastasis recti, are common [
         <a href="#rid1">
          1,12
         </a>
         ].
        </p>
        <p>
         Much of the information regarding cardiovascular problems in BWS is anecdotal. Cardiomegaly is commonly detected in infancy if a chest radiograph is done, but this typically resolves without treatment. There are rare reports of cardiomyopathy.
        </p>
        <p>
         Kidney anomalies include medullary dysplasia, duplicated collecting system, nephrocalcinosis, nephrolithiasis, medullary sponge kidney, cystic changes, and nephromegaly [
         <a href="#rid56">
          56-60
         </a>
         ]. Hypercalciuria can be found in children with BWS even in the absence of kidney abnormalities visualized by ultrasound [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
         Rare cases of posterior fossa brain abnormalities have been reported in patients with BWS who have involvement of the centromeric imprinted domain (domain 2) [
         <a href="#rid61">
          61
         </a>
         ]. (See
         <a class="local">
          'Genetics and pathogenesis'
         </a>
         above and
         <a class="local">
          'Development'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1351667">
         <span class="h2">
          Neoplasia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with BWS have an increased risk of mortality associated with neoplasia. Most commonly observed are Wilms tumor and hepatoblastoma, but also neuroblastoma, adrenocortical carcinoma, and rhabdomyosarcoma, as well as a wide variety of other tumors, both malignant and benign [
         <a href="#rid62">
          62
         </a>
         ]. The estimated risk for tumor development in children with BWS is 7.5 percent, with a range of risks between 4 and 21 percent [
         <a href="#rid4">
          4,62-70
         </a>
         ]. This increased risk for neoplasia is concentrated in the first eight years of life. Tumor development is uncommon in affected persons older than eight years of age; however, malignancies including Wilms tumor and
         <em>
         </em>
         hepatoblastoma
         <em>
         </em>
         have been reported in later childhood and adulthood [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1351674">
         <span class="h2">
          Development
         </span>
         <span class="headingEndMark">
          —
         </span>
         Development is usually normal in children with BWS unless there is a chromosome abnormality [
         <a href="#rid72">
          72,73
         </a>
         ], a posterior fossa abnormality [
         <a href="#rid61">
          61
         </a>
         ], or a history of hypoxia or significant, untreated hypoglycemia. Neurobehavioral issues, such as autism spectrum disorder, have been reported with increased frequency in children with BWS [
         <a href="#rid74">
          74
         </a>
         ]; however, these cases were ascertained by parental report only. Additional studies, including formal neurodevelopmental assessments, are needed to assess the frequencies of these issues in BWS.
        </p>
        <p class="headingAnchor" id="H1887409">
         <span class="h1">
          PHENOTYPE-(EPI)GENOTYPE CORRELATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of genetic and/or epigenetic alterations in growth regulatory genes on chromosome 11p15.5 are associated with specific phenotype-(epi)genotype correlations and different inheritance risks.
        </p>
        <p class="headingAnchor" id="H1887416">
         <span class="h2">
          Tumor development
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with uniparental disomy (UPD) of 11p15.5 or gain of methylation at the
         <em>
          H19
         </em>
         imprinting center (IC1) carry the highest risk of tumor development, primarily Wilms tumor or hepatoblastoma (approximately 16 and 30 percent, respectively) but also others including some benign tumors [
         <a href="#rid10">
          10,66,75-81
         </a>
         ]. Those with loss of maternal methylation at IC2 also carry an increased risk of approximately 2.6 percent for tumors. Though comparatively less frequent than in other molecular subtypes, Wilms tumor has now been reported in over 10 children with BWS and loss of maternal methylation at IC2 [
         <a href="#rid67">
          67
         </a>
         ]. In addition, hepatoblastoma has been reported in children with loss of maternal methylation at IC2 [
         <a href="#rid66">
          66
         </a>
         ]. Interpretation of the relatively low risk for Wilms tumor development associated with loss of methylation at IC2 varies across international jurisdictions, leading to divergent clinical practice in different countries. Specifically, surveillance beyond an initial baseline ultrasound is not recommended for children with loss of methylation at IC2 who reside in the United Kingdom and Europe, whereas these children are offered ongoing surveillance in North America (see
         <a class="local">
          'Surveillance'
         </a>
         below). Persons with pathogenic variants in
         <em>
          CDKN1C
         </em>
         have a low but increased risk of tumor formation, with primarily neuroblastoma reported. In addition, those with cytogenetically visible alterations have a very low risk for tumor development.
        </p>
        <p>
         Of note, children clinically suspected to have, or diagnosed with, BWS who have no detectable molecular alteration have a significant risk for tumor development. This is probably due to a lack of detection of somatic mosaicism for chromosome 11p15.5 UPD or other molecular anomalies in testing of peripheral blood samples.
        </p>
        <p>
         Tumor surveillance will undoubtedly become universally stratified by molecular etiology once reliably sensitive molecular methods are available along with optimized data for incidence by age from larger cohorts of children with BWS. (See
         <a class="local">
          'Surveillance'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1887423">
         <span class="h2">
          Hemihyperplasia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Somatic mosaicism for UPD of chromosome 11p15.5 resulting in methylation alterations at IC2 and IC1 is associated with hemihyperplasia [
         <a href="#rid11">
          11,82
         </a>
         ]. Less frequently, alterations in IC1 and IC2 are also seen in hemihyperplasia.
        </p>
        <p class="headingAnchor" id="H1887430">
         <span class="h2">
          Omphalocele
         </span>
         <span class="headingEndMark">
          —
         </span>
         IC2 alterations and
         <em>
          CDKN1C
         </em>
         pathogenic variants are associated with omphalocele [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H598376164">
         <span class="h2">
          Cleft palate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Only
         <em>
          CDKN1C
         </em>
         pathogenic variants have been reported in patients with BWS who have cleft palate [
         <a href="#rid84">
          84,85
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1887437">
         <span class="h2">
          Developmental delay
         </span>
         <span class="headingEndMark">
          —
         </span>
         Developmental delay is associated with cytogenetically detectable duplications involving the paternal copy of chromosome 11p15.5 [
         <a href="#rid11">
          11,73,74
         </a>
         ], although it may also be due to significant neonatal hypoglycemia or other perinatal complications, such as prematurity. In addition, developmental delay with posterior fossa brain abnormalities occurs rarely in association with IC2 alterations or
         <em>
          CDKN1C
         </em>
         pathogenic variants [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3456505564">
         <span class="h2">
          Undescended testes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Undescended testes are more common in males with IC2 or IC1 methylation alterations than in males with UPD of chromosome 11p15.5 or
         <em>
          CDKN1C
         </em>
         pathogenic variants. Undescended testes may reflect the increased rate of premature delivery for infants with BWS and methylation alterations [
         <a href="#rid71">
          71,81
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1887444">
         <span class="h2">
          Severe BWS phenotype
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cases of severe BWS have been reported in association with very high levels of somatic mosaicism for paternal UPD for chromosome 11p15.5 [
         <a href="#rid86">
          86,87
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1887451">
         <span class="h2">
          Positive family history
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most familial cases of BWS are due to pathogenic variants in
         <em>
          CDKN1C
         </em>
         or microdeletions of IC1 or, very rarely, IC2 microduplications [
         <a href="#rid11">
          11,14,16,17,84,88-90
         </a>
         ]. Vertical transmission of BWS can also occur with chromosome 11p15.5 translocations or inversions.
        </p>
        <p class="headingAnchor" id="H1887458">
         <span class="h2">
          Female monozygotic twins
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is a larger than expected number of female monozygotic twins discordant for BWS [
         <a href="#rid6">
          6
         </a>
         ]. The affected females usually demonstrate loss of methylation at IC2. In contrast, the less frequently observed male monozygotic twins show a broad spectrum of BWS-associated molecular alterations [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1887465">
         <span class="h2">
          Subfertility/assisted reproductive technology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Subfertility with or without use of assisted reproductive technology (ART) is associated with an increased risk of BWS cases due to loss of methylation at IC2 [
         <a href="#rid82">
          82,91-93
         </a>
         ]. It is not clear what specific aspects of subfertility or its treatment drive this association.
        </p>
        <p class="headingAnchor" id="H1513113044">
         <span class="h2">
          Pregnancy history
         </span>
         <span class="headingEndMark">
          —
         </span>
         A maternal history of recurrent spontaneous abortion and/or molar pregnancy may indicate heritable pathogenic variant(s) in a maternal effect gene leading to abnormal imprinting in BWS with multi-locus imprinting disturbance (MLID).
        </p>
        <p class="headingAnchor" id="H1619903">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The phenotype of BWS is highly variable. Given this variability and the ensuing challenges in determining medical management, a number of approaches have been developed to support the diagnostic process [
         <a href="#rid18">
          18
         </a>
         ]. One such approach includes the presence of three major clinical findings or two major and one minor finding for a clinical diagnosis of BWS, with the proviso that the diagnosis should be considered and tumor surveillance offered for children presenting with fewer findings [
         <a href="#rid1">
          1,41,94
         </a>
         ]. In 2018, a consensus group developed a numeric scoring algorithm for findings considered "cardinal" and those considered "suggestive," with the overall score guiding diagnostic categorization, molecular testing, and, potentially, management strategies [
         <a href="#rid18">
          18
         </a>
         ]. However, regardless of which set of diagnostic criteria are applied, children with "mild" or "low scoring" phenotypes may still have BWS and be at increased risk for tumor development [
         <a href="#rid49">
          49,81
         </a>
         ]. Thus, there should be a high index of suspicion when evaluating children with minimal clinical features in the BWS phenotypic spectrum, particularly if there is a positive family history (one or more family members with a clinical diagnosis of BWS or a history or features suggestive of BWS). In such cases, anticipatory medical management (eg, tumor surveillance) and molecular testing should be considered (see
         <a class="local">
          'Management'
         </a>
         below). As noted above, tumor surveillance should not be discontinued in the absence of a detectable molecular alteration.
        </p>
        <p>
         Approximately 15 percent of cases of BWS are familial. Thus, targeted information should be elicited regarding family history, including parental features during childhood, since these may normalize over time. In addition, type of conception (ie, natural versus assisted conception) and pregnancy-related findings, such as polyhydramnios, placental mesenchymal dysplasia [
         <a href="#rid48">
          48
         </a>
         ], and prematurity, should be ascertained. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above and
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1619017">
         <span class="h2">
          Genetic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Methylation-sensitive multiplex ligation probe analysis (MS-MLPA) is the most robust method clinically available for detecting the majority of epigenetic and genetic etiologies associated with BWS. MS-MLPA detects microdeletions/microduplications and alterations in gene dosage and DNA methylation including uniparental disomy (UPD) [
         <a href="#rid88">
          88
         </a>
         ]. Somatic mosaicism associated with UPD may lead to weak signals on MS-MLPA. UPD can be confirmed by analysis of short tandem repeats when it is suggested by methylation alterations at both imprinting centers 1 and 2 (IC1 and IC2). In addition, failure to detect a methylation alteration or UPD in one tissue (usually leukocytes) is not conclusive, especially in cases involving hemihyperplasia. One study noted that testing of multiple tissues increases the diagnostic yield from 70 to 82 percent, particularly in children with hemihyperplasia or with atypical presentations [
         <a href="#rid81">
          81
         </a>
         ]. Thus, testing of at least two tissues/cell populations, for example leukocytes and skin, is advised in patients with these features.
        </p>
        <p>
         MS-MLPA may not detect somatic mosaicism for 11p15 UPD; therefore, testing using single nucleotide polymorphism (SNP) arrays should be undertaken in parallel to support the interpretation of the IC1 and IC2 methylation data [
         <a href="#rid67">
          67,95,96
         </a>
         ]. Additionally, SNP array may identify genomewide UPD. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
         Rarely, microarray testing undertaken for a clinical reason unrelated to BWS reveals a copy number variation (CNV; a microdeletion or microduplication) involving 11p15.5. In such situations, a clinical diagnosis of BWS would not be assigned when careful evaluation does not reveal any BWS-associated clinical findings. However, tumor surveillance (see
         <a class="local">
          'Surveillance'
         </a>
         below) is suggested given that Wilms tumor has been reported in children with constitutional 11p15.5 molecular alterations in the absence of other BWS clinical features [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
         Karyotype analysis is required to detect the rare de novo and maternally transmitted translocations/inversions and will also detect paternally derived duplications of chromosome 11p15.5 associated with BWS. Translocations/inversions almost always disrupt the gene potassium channel voltage-gated
         <em>
          KCNQ1
         </em>
         [
         <a href="#rid26">
          26
         </a>
         ] and
         <strong>
         </strong>
         are not usually detectable by MS-MLPA, because most do not demonstrate DNA copy number changes or DNA methylation changes.
        </p>
        <p>
         DNA sequencing is required to detect genomic alterations
         <strong>
         </strong>
         in the
         <em>
          CDKN1C
         </em>
         gene associated with BWS.
         <em>
          CDKN1C
         </em>
         pathogenic variants are seen both sporadically (5 percent of cases) and in autosomal-dominant pedigrees modified by preferential parent of origin-specific transmission (40 percent of cases) [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p>
         Targeted clinical testing for maternal effect genes is not available. However, whole-exome sequencing or whole-genome sequencing should be considered based on clinical findings (eg, hyperglycemia, hypocalcemia), family history, and/or maternal reproductive history (eg, recurrent pregnancy loss, molar pregnancy). Such testing may identify compound heterozygous pathogenic variants in maternal effect genes leading to aberrant imprinting. The cost-benefit of using methylation arrays as a clinical test to investigate possible MLID remains to be determined as the prevalence of MLID associated findings appears to be rare, and MLID may vary across tissues. Further research in this area will help defining clinical recommendations for diagnostic testing.
        </p>
        <p class="headingAnchor" id="H1887889">
         <span class="h2">
          Prenatal diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Indications for prenatal testing may include a previous child with BWS or a positive family history of BWS. Prenatal testing may be undertaken by chorionic villus sampling (CVS) or amniocentesis, if the cytogenetic or genomic abnormality (eg, microdeletion,
         <em>
          CDKN1C
         </em>
         pathogenic variant) in the affected family member is known. Epigenetic analysis of chromosome 11p15.5 in amniocytes is sufficiently reliable for prenatal diagnosis [
         <a href="#rid97">
          97
         </a>
         ], with the caution that mosaicism can confound the reliability of the test result [
         <a href="#rid98">
          98
         </a>
         ]. Analysis of methylation alterations in CVS requires further validation before this can be offered as a clinical test since methylation status of chromosome 11p15.5 ICs is known to vary significantly in extra-embryonic tissues in early pregnancy.
        </p>
        <p>
         Prenatal testing via amniocentesis may also be indicated for BWS-associated findings detected on fetal ultrasound, such as omphalocele, kidney enlargement, or macroglossia [
         <a href="#rid99">
          99
         </a>
         ]. A follow-up study of apparently isolated fetal omphalocele (ie, no known family history of BWS and no additional findings detected on fetal ultrasound) reported BWS in 20 percent of cases based upon subsequent clinical evaluation and/or molecular testing [
         <a href="#rid100">
          100
         </a>
         ]. Thus, molecular testing is suggested in such cases.
        </p>
        <p>
         Prenatal screening is an option if the molecular defect is not known or if invasive prenatal testing is not undertaken. This screening includes ultrasound evaluation for assessment of growth parameters that may become advanced for gestational age (usually after 24 weeks), abdominal wall defects, organomegaly, kidney abnormalities, cleft palate, cardiac anomalies, and macroglossia [
         <a href="#rid45">
          45
         </a>
         ]. Nuchal translucency measurements between 10 to 14 weeks can be informative [
         <a href="#rid101">
          101
         </a>
         ], and detailed ultrasound is typically performed at 18 to 20 weeks and again at 25 to 32 weeks gestation. Measurement of maternal serum alpha fetoprotein (AFP), elevated in association with abdominal wall defects, may provide additional information, although imaging detects virtually all cases of omphalocele [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H22939447">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presentation of a newborn with large growth parameters  (
         <a class="graphic graphic_table graphicRef53324" href="/z/d/graphic/53324.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef62919" href="/z/d/graphic/62919.html" rel="external">
          table 2
         </a>
         ), macroglossia, and/or hypoglycemia should prompt a comprehensive clinical examination followed by relevant investigations. A number of endocrine disorders and overgrowth syndromes should be considered in the differential diagnosis, including maternal diabetes mellitus and congenital hypothyroidism. (See
         <a class="medical medical_review" href="/z/d/html/5058.html" rel="external">
          "Infants of mothers with diabetes (IMD)"
         </a>
         .)
        </p>
        <p>
         Several genetic syndromes have features in common with BWS but can be distinguished by genetic testing, ancillary tests (eg, brain imaging, molecular, and/or biochemical testing), and follow-up for the appearance of defining features. Neurofibromatosis type 1, Proteus syndrome,
         <em>
          PIK3CA
         </em>
         -related overgrowth spectrum (PROS), and
         <em>
          PTEN
         </em>
         hamartoma tumor syndrome (PHTS) are all syndromes that can have associated hemihyperplasia. Perlman syndrome, Sotos syndrome, Simpson-Golabi-Behmel syndrome, mosaic genome-wide paternal uniparental disomy (UPD), and isolated hemihyperplasia all are associated with an increased risk of Wilms tumor. (See
         <a class="medical medical_review" href="/z/d/html/6249.html" rel="external">
          "Presentation, diagnosis, and staging of Wilms tumor", section on 'Other congenital anomalies'
         </a>
         .)
        </p>
        <p>
         The differential diagnosis includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Isolated hemihyperplasia (MIM #235000; also termed isolated lateralized overgrowth) – Evaluation should be undertaken for the presence of clinical findings that may indicate a syndromic diagnosis, especially as this may influence management [
         <a href="#rid102">
          102
         </a>
         ]. For patients with asymmetry as an isolated finding, it is important to determine if the asymmetry represents overgrowth (hemihyperplasia) [
         <a href="#rid53">
          53,103-105
         </a>
         ] or decreased growth (hemihypoplasia) since the latter is not associated with an increased risk for tumor development. Molecular testing may provide clarification in that hemihypoplasia is sometimes associated with hypomethylation of imprinting center (IC) 1, whereas hemihyperplasia is associated with hypermethylation of IC1 or chromosome 11p15.5 UPD [
         <a href="#rid106">
          106
         </a>
         ]. (See
         <a class="local">
          'Growth'
         </a>
         above and
         <a class="local">
          'Genetic testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mosaic genome-wide paternal UPD – Testing for genome-wide UPD is advised if features of BWS are associated with additional findings (eg, higher incidence of tumors that occur into later childhood and adulthood and that are of different types than that typically seen in BWS, hyperinsulinism) suggestive of a complex genomic etiology [
         <a href="#rid107">
          107-110
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Simpson-Golabi-Behmel syndrome (type 1 MIM #312870; type 2 MIM #300209) – Defining features of this syndrome include craniofacial anomalies (macrocephaly; coarse facies; ocular hypertelorism; broad, flat nose; macrostomia; macroglossia; cleft lip), kidney anomalies, moderate intellectual disability, and other congenital malformations. (See
         <a class="medical medical_review" href="/z/d/html/6083.html" rel="external">
          "Renal hypodysplasia", section on 'Genetic disorders'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Costello syndrome (MIM #218040) – Features suggestive of Costello syndrome include coarse facies; loose skin; diffuse hypotonia; joint laxity; sparse, fine hair; failure to thrive; and nonprogressive cardiomyopathy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perlman syndrome (MIM #267000) – Common characteristics seen in patients with Perlman syndrome include unusual facies (depressed nasal bridge, anteverted upper lip, mild micrognathia) and intellectual disability.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Weaver syndrome (MIM #277590) – Patients with Weaver syndrome have overgrowth involving both height and head circumference, as well as camptodactyly (fixed flexion deformity of the proximal interphalangeal joints) and increased risk of leukemia.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22939583">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H22939591">
         <span class="h2">
          Evaluation following initial diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following evaluations are advised to establish the extent of disease in an individual diagnosed with BWS:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assessment for airway sufficiency in the presence of macroglossia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation by a feeding specialist if macroglossia causes significant feeding difficulties.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assessment of neonates for hypoglycemia; evaluation by a pediatric endocrinologist if hypoglycemia is severe or persists beyond the first few days of life.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abdominal ultrasound examination to assess for organomegaly, structural abnormality, and tumors. A baseline magnetic resonance imaging (MRI) or computed tomography (CT) examination of the abdomen to screen for tumors may be considered at the time of diagnosis or later [
         <a href="#rid111">
          111
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If diagnosis is made in late adolescence or adulthood, kidney ultrasound should be undertaken to screen for abnormalities such as nephrolithiasis and medullary sponge kidney.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Comprehensive cardiac evaluation including electrocardiogram (ECG) and echocardiogram prior to any surgical procedures or when a cardiac abnormality is suspected on baseline or follow-up clinical evaluation. While congenital arrhythmia disorders such as long QT syndrome (LQTS) are rarely reported in BWS [
         <a href="#rid112">
          112
         </a>
         ], there are several reports of LQTS in persons with BWS and genomic alterations disrupting
         <em>
          KCNQ1
         </em>
         transcription.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alpha fetoprotein (AFP) assay at the time of initial diagnosis to assess for hepatoblastoma.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hemihyperplasia involving leg-length discrepancy should be monitored periodically, particularly during periods of active overall growth and when associated with paternal UPD of 11p15.5 [
         <a href="#rid113">
          113
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinicians should be aware of the rare occurrence of metabolic abnormalities (eg. hyperglycemia [transient neonatal diabetes mellitus (TNDM)] or hypocalcemia [pseudohypoparathyroidism]) in persons with BWS who may have multi-locus imprinting disturbance (MLID) in order to appropriately investigate.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22939600">
         <span class="h2">
          Treatment of manifestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following measures are advised for disease manifestations that may appear throughout the course of the disease:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prompt treatment of hypoglycemia to reduce the risk of central nervous system complications. The onset of hypoglycemia is variable, and therefore parents should be informed of the symptoms of hypoglycemia so that they know when to seek appropriate medical attention for their child.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abdominal wall repair soon after birth for omphalocele. This surgery is generally well tolerated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management of difficulties arising from macroglossia:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Anticipation of difficulties with endotracheal intubation [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pulmonary assessment, possibly including sleep study, to address concerns regarding potential sleep apnea.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Management of feeding difficulties using specialized nipples, such as the longer nipple recommended for babies with cleft palate or, rarely, short-term use of nasogastric tube feedings.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Follow-up by a craniofacial team including plastic surgeons, orthodontists, and speech pathologists familiar with the natural history of BWS. Some children benefit from tongue reduction surgery; however, surgical reduction typically impacts tongue length, not thickness. Residual cosmetic, orthodontic, and speech issues may require further assessment/treatment [
         <a href="#rid115">
          115
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Consultation with an orthopedic surgeon if hemihyperplasia results in a significant difference in leg length. Surgery may be necessary during early puberty to close the growth plate of the longer leg in order to equalize the final leg lengths. An alternative option is leg lengthening of the shorter leg.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Referral to a craniofacial surgeon if facial hemihyperplasia is significant.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of neoplasia following standard pediatric oncology protocols.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Standard interventions, such as infant stimulation programs, occupational and physical therapy, and individualized education programs for children with developmental delay.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Referral of children with structural kidney or gastrointestinal tract abnormalities to the relevant specialists.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22939609">
         <span class="h2">
          Surveillance
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following surveillance is advised in patients with BWS:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monitor for hypoglycemia in the first few days of life by random blood glucose measurements to detect asymptomatic hypoglycemia and have a higher index of suspicion for/awareness of clinical signs of hypoglycemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Screen for developmental issues as part of routine childcare, especially when there is a history of hypoglycemia, prematurity, or evidence of chromosome 11p15.5 duplication.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Screen for embryonal tumors [
         <a href="#rid116">
          116
         </a>
         ]. Screening protocols vary in different geographic locations (see
         <a class="local">
          'Tumor development'
         </a>
         above). In some centers, screening is modified based upon molecular test results. Specifically, in many countries in Europe, a tumor risk of at least 5 percent is required for surveillance to be undertaken. Therefore, in these geographic regions, tumor surveillance is typically not recommended for children with loss of methylation at imprinting center 2 (IC2) beyond baseline abdominal ultrasound [
         <a href="#rid18">
          18,117
         </a>
         ]. As well, serial alpha fetoprotein assay is variably included at different centers in the surveillance protocols for children with BWS. In North America, tumor surveillance is generally undertaken every three months to the seventh birthday or through the seventh year for all children with BWS regardless of the molecular alteration detected (including no detectable alteration) given that the risk for tumor development is greater than 1 percent [
         <a href="#rid67">
          67,116
         </a>
         ]. As well, the risk of approximately 3 percent for Wilms tumor and hepatoblastoma in children with loss of methylation at IC2 represents an 11-fold increase to that seen in the general pediatric population [
         <a href="#rid118">
          118,119
         </a>
         ]. This recommended surveillance approach is detailed below and includes both serial imaging and alpha fetoprotein assay given that early detection of hepatoblastoma and Wilms tumor have been shown to positively impact treatment outcomes [
         <a href="#rid120">
          120
         </a>
         ]. Evidence-based decisions regarding tumor surveillance must await the results of a properly designed, prospective, large-scale study and improved molecular diagnostic test modalities.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Abdominal ultrasound examination every three months until age four years [
         <a href="#rid64">
          64,111,121,122
         </a>
         ] and then kidney ultrasound including the adrenal glands every three months to the seventh birthday or through the seventh year [
         <a href="#rid67">
          67,116,123
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Measure serum AFP concentration every two to three months in the first four years of life for early detection of hepatoblastoma [
         <a href="#rid121">
          121
         </a>
         ]. This recommendation may be revised if there is replication of one study suggesting that hepatoblastoma screening until 30 months of age captures all cases of hepatoblastoma [
         <a href="#rid124">
          124
         </a>
         ]. AFP serum concentration may be mildly elevated in children with BWS in the first year of life in the absence of a hepatoblastoma [
         <a href="#rid125">
          125
         </a>
         ]. If the AFP is elevated in the absence of a suspicious lesion on imaging, follow-up measurement of serum AFP concentration plus baseline liver function tests four to six weeks later can be used to determine the trend in serum AFP concentrations over time. If a decline in AFP concentration is not seen, it is appropriate to refer to an oncologist and/or undertake an exhaustive search for an underlying tumor [
         <a href="#rid126">
          126
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Periodic chest radiograph and urinary homovanillic acid (HVA) and vanilmandelic acid (VMA) assays to screen for neuroblastoma have been suggested but have not been incorporated into most screening protocols, because of their low yield and the challenges of high rates of false-positive testing.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         While serial tumor surveillance is typically discontinued after the seventh or eighth birthday, a heightened degree of clinical suspicion should be maintained for any concerns potentially indicating a malignancy, and these should be investigated promptly.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assess for kidney anomalies as part of the abdominal ultrasound examination for embryonal tumor screening in patients eight years of age and under. Assess individuals over eight years of age through adolescence with annual or biennial (ie, every two years) kidney ultrasound examination to identify those requiring further evaluation/management since nephrocalcinosis, nephrolithiasis, and medullary sponge kidney develop at a later age.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Consider measurement of urinary calcium/creatinine ratio annually or biannually since it may be abnormal in individuals with kidney disease who have normal kidney ultrasound examinations [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Annual ECG and cardiac evaluation are suggested for persons with BWS associated with genomic alterations involving the IC2 region [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Periodic assessment of leg lengths on physical examination or by caregiver report.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Consideration should be given to offering tumor surveillance for those cases presenting with a "mild" phenotype (see
         <a class="local">
          'Diagnosis'
         </a>
         above). Additionally, tumor surveillance is suggested for the clinically unaffected monozygotic twin of a child with BWS because of the possibility of low-level mosaicism and shared-fetal circulation [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22939618">
         <span class="h2">
          Genetic counseling
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genetic counseling regarding BWS etiology and recurrence risk (ie, risk of a subsequent affected child) is most accurate if data from a complete diagnostic evaluation are available, including molecular testing. These data include family history, clinical findings, karyotype, methylation-sensitive multiplex ligation probe analysis (MS-MLPA), single nucleotide polymorphism (SNP) array, and
         <em>
          CDKN1C
         </em>
         variant analysis if indicated.
        </p>
        <p>
         The recurrence risk is low if molecular testing reveals uniparental disomy (UPD) or a methylation alteration in the absence of a transmissible genomic alteration. Information regarding recurrence risk for some of the molecular subtypes remains theoretical since there is a paucity of confirmatory empiric data. This is especially relevant when providing genetic counseling for affected individuals with theoretically low recurrence risk (eg, UPD for chromosome 11p15, methylation alterations at IC2). Molecular testing is typically not indicated for parents or other family members when UPD is found, since these cases arise via postzygotic somatic recombination. Parental studies are recommended if genomic alterations are found (eg, karyotype abnormalities,
         <em>
          CDKN1C
         </em>
         variants, or microduplications or microdeletions of the chromosome 11p15.5 region).
        </p>
        <p>
         Molecular alterations that are associated with significant recurrence risk include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maternal transmission of chromosome 11p15.5 translocation/inversion [
         <a href="#rid4">
          4
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maternal transmission of
         <em>
          CDKN1C
         </em>
         variant [
         <a href="#rid89">
          89
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chromosome 11p15.5 duplication of paternal origin [
         <a href="#rid73">
          73
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         11p15.5 microdeletion/microduplication [
         <a href="#rid16">
          16
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Molecular testing or chromosome analysis is indicated for both parents and potentially other family members if either a translocation or inversion involving chromosome 11p15.5 or a
         <em>
          CDKN1C
         </em>
         variant is found in the proband. The recurrence risk is 50 percent for
         <em>
          CDKN1C
         </em>
         variants and for translocations or inversions involving chromosome 11p15.5 if the transmitting parent is the mother [
         <a href="#rid89">
          89
         </a>
         ]. The risk is low if the
         <em>
          CDKN1C
         </em>
         variant is found in the father; however, at least one case of BWS and paternal transmission of a
         <em>
          CDKN1C
         </em>
         variant has been reported in the literature [
         <a href="#rid90">
          90
         </a>
         ]. The recurrence risk for paternally derived duplications is not specifically defined but is probably significant if the father carries a translocation. Familial transmissions involving microdeletions of IC1, and rarely of IC2, have been reported. Thus, parental testing is indicated when these alterations are identified [
         <a href="#rid16">
          16,17,88
         </a>
         ].
        </p>
        <p>
         The recurrence risk can be estimated empirically in the case of a positive family history in the absence of an abnormal genetic test result. Information incorporated into such estimates includes the sex and potential carrier status of the transmitting parent. All potential etiologies consistent with the positive family history should be considered. The recurrence risk for BWS in cases where there is no identified cause may be as high as 50 percent. Gonadal mosaicism remains a possibility, although it has not been reported to date. It should be considered when there is more than one affected offspring and/or the parents are not found to carry a transmissible microdeletion or variant associated with BWS.
        </p>
        <p>
         When a pathogenic variant is detected in a maternal effect gene, genetic counseling should include information regarding the increased risk for adverse reproductive outcomes such as pregnancy loss or molar pregnancy as well as the risk for children with imprinting disorders [
         <a href="#rid33">
          33
         </a>
         ]. Molecular testing (DNA methylation) for imprinting status, including prenatal testing, can be confounded by somatic mosaicism and the heterogeneous molecular etiologies [
         <a href="#rid33">
          33
         </a>
         ]. Our understanding of the impact of maternal effect gene variants and the molecular testing for such variants will evolve based upon research efforts.
        </p>
        <p class="headingAnchor" id="H1351427">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infants with BWS are at increased risk for mortality mainly due to complications of prematurity, macroglossia, hypoglycemia, tumors, and, rarely, cardiomyopathy. A previously reported mortality rate of 20 percent may be an overestimate given the improvements in syndrome recognition and treatment [
         <a href="#rid4">
          4,43,87
         </a>
         ]. Prognosis is generally favorable after childhood. However, complications in adolescence/adulthood can occur (eg, kidney medullary dysplasia, subfertility in males). Such issues may be associated with specific molecular subtypes [
         <a href="#rid127">
          127
         </a>
         ]. (See
         <a class="local">
          'Phenotype-(epi)genotype correlations'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2937387412">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/118546.html" rel="external">
          "Society guideline links: Beckwith-Wiedemann syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1620147">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Beckwith-Wiedemann syndrome (BWS) is a pediatric overgrowth disorder involving a predisposition to tumor development. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – BWS usually occurs sporadically, but familial transmission occurs in approximately 15 percent of cases. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetics
         </strong>
         – Dysregulation of imprinted genes within the chromosome 11p15.5 region results in the BWS phenotype. However, a chromosome 11p15 molecular alteration is identified in only approximately 80 percent of persons with BWS. This may be due to low-level somatic mosaicism in the tissue sampled for testing or to other genomic loci that are probably involved in the etiology of BWS. (See
         <a class="local">
          'Genetics and pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – The hallmark features of BWS are omphalocele (exomphalos), macroglossia, and macrosomia (gigantism). However, the clinical presentation is highly variable, and some cases lack these characteristic features. Children with otherwise mild phenotypes can present with tumors. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phenotype-(epi)genotype correlations
         </strong>
         – A number of genetic and/or epigenetic alterations in growth regulatory genes on chromosome 11p15.5 are associated with specific phenotype-(epi)genotype correlations and different recurrence risks. Information is emerging regarding genetic etiologies involving loci outside of the 11p15.5 region. (See
         <a class="local">
          'Phenotype-(epi)genotype correlations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – Several diagnostic approaches have been developed to address the challenges associated with the heterogeneous clinical presentation of BWS. However, children with minimal features not meeting diagnostic criteria may still develop a tumor, and therefore a cautious approach is advised. Molecular testing can be performed to determine the precise genetic defect and confirm the diagnosis. Methylation-sensitive multiplex ligation probe analysis (MS-MLPA) is the most robust method available for detecting most epigenetic and genetic etiologies associated with BWS. Prenatal testing is available, although consideration should be given to test modality for genomic versus methylation alteration. In addition, somatic mosaicism can confound test reliability. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis includes both genetic and nongenetic causes of macrosomia  (
         <a class="graphic graphic_table graphicRef53324" href="/z/d/graphic/53324.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef62919" href="/z/d/graphic/62919.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Initial evaluation includes assessment for hypoglycemia, airway sufficiency, feeding difficulties, and screening for tumors. Surveillance includes monitoring for hypoglycemia, tumors, developmental issues, and kidney disease. Disease manifestations that appear throughout the course of the disease, including hypoglycemia, macroglossia, hemihyperplasia, and neoplasia, are treated with the normal standard of care. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic counseling
         </strong>
         – Cases involving uniparental disomy (UPD) arise from postzygotic somatic recombination and are therefore not known to be associated with a significantly increased risk for recurrence. Parental studies are recommended if genomic alterations are found (eg, karyotype abnormalities, cyclin-dependent kinase inhibitor 1C [
         <em>
          CDKN1C
         </em>
         ] variants, or microduplications or microdeletions of the chromosome 11p15.5 region), and these test results are then incorporated into estimates of recurrence risks. (See
         <a class="local">
          'Genetic counseling'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Infants with BWS are at increased risk for mortality, mainly due to complications of prematurity, macroglossia, hypoglycemia, tumors, and, rarely, cardiomyopathy. The increased risk for neoplasia is concentrated in the first eight years of life. Thus, prognosis is generally favorable after early childhood. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Weksberg R, Shuman C, Beckwith JB. Beckwith-Wiedemann syndrome. Eur J Hum Genet 2010; 18:8.
          </a>
         </li>
         <li class="breakAll">
          Beckwith JB. Extreme cytomegaly of the adrenal fetal cortex, omphalocele, hyperplasia of kidneys and pancreas, and Leydig-cell hyperplasia: Another syndrome? (Abstract), Western Society for Pediatric Research (Ed), Los Angeles 1963.
         </li>
         <li>
          <a class="nounderline abstract_t">
           WIEDEMANN HR. [FAMILIAL MALFORMATION COMPLEX WITH UMBILICAL HERNIA AND MACROGLOSSIA--A "NEW SYNDROME"?]. J Genet Hum 1964; 13:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pettenati MJ, Haines JL, Higgins RR, et al. Wiedemann-Beckwith syndrome: presentation of clinical and cytogenetic data on 22 new cases and review of the literature. Hum Genet 1986; 74:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mussa A, Russo S, De Crescenzo A, et al. Prevalence of Beckwith-Wiedemann syndrome in North West of Italy. Am J Med Genet A 2013; 161A:2481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weksberg R, Shuman C, Caluseriu O, et al. Discordant KCNQ1OT1 imprinting in sets of monozygotic twins discordant for Beckwith-Wiedemann syndrome. Hum Mol Genet 2002; 11:1317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortessis VK, Azadian M, Buxbaum J, et al. Comprehensive meta-analysis reveals association between multiple imprinting disorders and conception by assisted reproductive technology. J Assist Reprod Genet 2018; 35:943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mussa A, Molinatto C, Cerrato F, et al. Assisted Reproductive Techniques and Risk of Beckwith-Wiedemann Syndrome. Pediatrics 2017; 140.
          </a>
         </li>
         <li class="breakAll">
          http://geneimprint.com/site/genes-by-species (Accessed on June 11, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper WN, Luharia A, Evans GA, et al. Molecular subtypes and phenotypic expression of Beckwith-Wiedemann syndrome. Eur J Hum Genet 2005; 13:1025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Enklaar T, Zabel BU, Prawitt D. Beckwith-Wiedemann syndrome: multiple molecular mechanisms. Expert Rev Mol Med 2006; 8:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weksberg R, Shuman C, Smith AC. Beckwith-Wiedemann syndrome. Am J Med Genet C Semin Med Genet 2005; 137C:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weksberg R, Smith AC, Squire J, Sadowski P. Beckwith-Wiedemann syndrome demonstrates a role for epigenetic control of normal development. Hum Mol Genet 2003; 12 Spec No 1:R61.
          </a>
         </li>
         <li class="breakAll">
          Weksberg R, Shuman C. Beckwith-Wiedemann syndrome and hemihypertrophy. In: Management of genetic syndromes, 2nd ed, Cassidy SB, Allanson JE (Eds), John Wiley &amp; Sons, Inc, New York 2005.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niemitz EL, DeBaun MR, Fallon J, et al. Microdeletion of LIT1 in familial Beckwith-Wiedemann syndrome. Am J Hum Genet 2004; 75:844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prawitt D, Enklaar T, Gärtner-Rupprecht B, et al. Microdeletion of target sites for insulator protein CTCF in a chromosome 11p15 imprinting center in Beckwith-Wiedemann syndrome and Wilms' tumor. Proc Natl Acad Sci U S A 2005; 102:4085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sparago A, Cerrato F, Vernucci M, et al. Microdeletions in the human H19 DMR result in loss of IGF2 imprinting and Beckwith-Wiedemann syndrome. Nat Genet 2004; 36:958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brioude F, Kalish JM, Mussa A, et al. Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome: an international consensus statement. Nat Rev Endocrinol 2018; 14:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baskin B, Choufani S, Chen YA, et al. High frequency of copy number variations (CNVs) in the chromosome 11p15 region in patients with Beckwith-Wiedemann syndrome. Hum Genet 2014; 133:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen J, Xu J, Yu Y, Sun L. Case Report: A Novel Deletion in the 11p15 Region Causing a Familial Beckwith-Wiedemann Syndrome. Front Genet 2021; 12:621096.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang H, Ping Z, Wang J, et al. A Beckwith-Wiedemann syndrome case with de novo 24 Mb duplication of chromosome 11p15.5p14.3. Mol Cytogenet 2021; 14:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eggermann T, Begemann M, Pfeiffer L. Unusual deletion of the maternal 11p15 allele in Beckwith-Wiedemann syndrome with an impact on both imprinting domains. Clin Epigenetics 2021; 13:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hark AT, Schoenherr CJ, Katz DJ, et al. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 2000; 405:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abi Habib W, Azzi S, Brioude F, et al. Extensive investigation of the IGF2/H19 imprinting control region reveals novel OCT4/SOX2 binding site defects associated with specific methylation patterns in Beckwith-Wiedemann syndrome. Hum Mol Genet 2014; 23:5763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kraft F, Wesseler K, Begemann M, et al. Novel familial distal imprinting centre 1 (11p15.5) deletion provides further insights in imprinting regulation. Clin Epigenetics 2019; 11:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smilinich NJ, Day CD, Fitzpatrick GV, et al. A maternally methylated CpG island in KvLQT1 is associated with an antisense paternal transcript and loss of imprinting in Beckwith-Wiedemann syndrome. Proc Natl Acad Sci U S A 1999; 96:8064.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diaz-Meyer N, Day CD, Khatod K, et al. Silencing of CDKN1C (p57KIP2) is associated with hypomethylation at KvDMR1 in Beckwith-Wiedemann syndrome. J Med Genet 2003; 40:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bliek J, Maas S, Alders M, et al. Epigenotype, phenotype, and tumors in patients with isolated hemihyperplasia. J Pediatr 2008; 153:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naik S, Riordan-Eva E, Thomas NS, et al. Large de novo deletion of 7p15.1 to 7p12.1 involving the imprinted gene GRB10 associated with a complex phenotype including features of Beckwith Wiedemann syndrome. Eur J Med Genet 2011; 54:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lirussi F, Jonard L, Gaston V, et al. Beckwith-Wiedemann-like macroglossia and 18q23 haploinsufficiency. Am J Med Genet A 2007; 143A:2796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanchez-Delgado M, Riccio A, Eggermann T, et al. Causes and Consequences of Multi-Locus Imprinting Disturbances in Humans. Trends Genet 2016; 32:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fontana L, Bedeschi MF, Maitz S, et al. Characterization of multi-locus imprinting disturbances and underlying genetic defects in patients with chromosome 11p15.5 related imprinting disorders. Epigenetics 2018; 13:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elbracht M, Mackay D, Begemann M, et al. Disturbed genomic imprinting and its relevance for human reproduction: causes and clinical consequences. Hum Reprod Update 2020; 26:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choufani S, Ko JM, Lou Y, et al. Paternal Uniparental Disomy of the Entire Chromosome 20 in a Child with Beckwith-Wiedemann Syndrome. Genes (Basel) 2021; 12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bebbere D, Masala L, Albertini DF, Ledda S. The subcortical maternal complex: multiple functions for one biological structure? J Assist Reprod Genet 2016; 33:1431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Docherty LE, Kabwama S, Lehmann A, et al. Clinical presentation of 6q24 transient neonatal diabetes mellitus (6q24 TNDM) and genotype-phenotype correlation in an international cohort of patients. Diabetologia 2013; 56:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Begemann M, Rezwan FI, Beygo J, et al. Maternal variants in NLRP and other maternal effect proteins are associated with multilocus imprinting disturbance in offspring. J Med Genet 2018; 55:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eggermann T, Kadgien G, Begemann M, Elbracht M. Biallelic PADI6 variants cause multilocus imprinting disturbances and miscarriages in the same family. Eur J Hum Genet 2021; 29:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cubellis MV, Pignata L, Verma A, et al. Loss-of-function maternal-effect mutations of PADI6 are associated with familial and sporadic Beckwith-Wiedemann syndrome with multi-locus imprinting disturbance. Clin Epigenetics 2020; 12:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rezaei M, Suresh B, Bereke E, et al. Novel pathogenic variants in NLRP7, NLRP5, and PADI6 in patients with recurrent hydatidiform moles and reproductive failure. Clin Genet 2021; 99:823.
          </a>
         </li>
         <li class="breakAll">
          Shuman C, Beckwith JB, Weksberg R.. GeneReviews®, Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A. (Eds), University of Washington, Seattle, Seattle (WA) 1993.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elliott M, Bayly R, Cole T, et al. Clinical features and natural history of Beckwith-Wiedemann syndrome: presentation of 74 new cases. Clin Genet 1994; 46:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weng EY, Moeschler JB, Graham JM Jr. Longitudinal observations on 15 children with Wiedemann-Beckwith syndrome. Am J Med Genet 1995; 56:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abbasi N, Moore A, Chiu P, et al. Prenatally diagnosed omphaloceles: Report of 92 cases and association with Beckwith-Wiedemann syndrome. Prenat Diagn 2021; 41:798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shieh HF, Estroff JA, Barnewolt CE, et al. Prenatal imaging throughout gestation in Beckwith-Wiedemann syndrome. Prenat Diagn 2019; 39:792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colpaert RM, Ramseyer AM, Luu T, et al. Diagnosis and Management of Placental Mesenchymal Disease. A Review of the Literature. Obstet Gynecol Surv 2019; 74:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kodera C, Aoki S, Ohba T, et al. Clinical manifestations of placental mesenchymal dysplasia in Japan: A multicenter case series. J Obstet Gynaecol Res 2021; 47:1118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson M, Peters G, Bennetts B, et al. The clinical phenotype of mosaicism for genome-wide paternal uniparental disomy: two new reports. Am J Med Genet A 2008; 146A:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fontana L, Tabano S, Maitz S, et al. Clinical and Molecular Diagnosis of Beckwith-Wiedemann Syndrome with Single- or Multi-Locus Imprinting Disturbance. Int J Mol Sci 2021; 22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chitayat D, Rothchild A, Ling E, et al. Apparent postnatal onset of some manifestations of the Wiedemann-Beckwith syndrome. Am J Med Genet 1990; 36:434.
          </a>
         </li>
         <li class="breakAll">
          Weksberg R, The Hospital for Sick Children, Toronto, personal communication, 2010.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalish JM, Biesecker LG, Brioude F, et al. Nomenclature and definition in asymmetric regional body overgrowth. Am J Med Genet A 2017; 173:1735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoyme HE, Seaver LH, Jones KL, et al. Isolated hemihyperplasia (hemihypertrophy): report of a prospective multicenter study of the incidence of neoplasia and review. Am J Med Genet 1998; 79:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engström W, Lindham S, Schofield P. Wiedemann-Beckwith syndrome. Eur J Pediatr 1988; 147:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez y Martínez R, Ocampo-Campos R, Pérez-Arroyo R, et al. The Wiedemann-Beckwith syndrome in four sibs including one with associated congenital hypothyroidism. Eur J Pediatr 1985; 143:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldman M, Shuman C, Weksberg R, Rosenblum ND. Hypercalciuria in Beckwith-Wiedemann syndrome. J Pediatr 2003; 142:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borer JG, Kaefer M, Barnewolt CE, et al. Renal findings on radiological followup of patients with Beckwith-Wiedemann syndrome. J Urol 1999; 161:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choyke PL, Siegel MJ, Oz O, et al. Nonmalignant renal disease in pediatric patients with Beckwith-Wiedemann syndrome. AJR Am J Roentgenol 1998; 171:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong CA, Cuda S, Kirsch A. A review of the urologic manifestations of Beckwith-Wiedemann syndrome. J Pediatr Urol 2011; 7:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mussa A, Peruzzi L, Chiesa N, et al. Nephrological findings and genotype-phenotype correlation in Beckwith-Wiedemann syndrome. Pediatr Nephrol 2012; 27:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gardiner K, Chitayat D, Choufani S, et al. Brain abnormalities in patients with Beckwith-Wiedemann syndrome. Am J Med Genet A 2012; 158A:1388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen MM Jr. Beckwith-Wiedemann syndrome: historical, clinicopathological, and etiopathogenetic perspectives. Pediatr Dev Pathol 2005; 8:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sotelo-Avila C, Gonzalez-Crussi F, Fowler JW. Complete and incomplete forms of Beckwith-Wiedemann syndrome: their oncogenic potential. J Pediatr 1980; 96:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan TY, Amor DJ. Tumour surveillance in Beckwith-Wiedemann syndrome and hemihyperplasia: a critical review of the evidence and suggested guidelines for local practice. J Paediatr Child Health 2006; 42:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiedemann HR. Tumours and hemihypertrophy associated with Wiedemann-Beckwith syndrome (Letter to the Editor). Eur J Pediatr 1983; 141:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maas SM, Vansenne F, Kadouch DJ, et al. Phenotype, cancer risk, and surveillance in Beckwith-Wiedemann syndrome depending on molecular genetic subgroups. Am J Med Genet A 2016; 170:2248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brzezinski J, Shuman C, Choufani S, et al. Wilms tumour in Beckwith-Wiedemann Syndrome and loss of methylation at imprinting centre 2: revisiting tumour surveillance guidelines. Eur J Hum Genet 2017; 25:1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mussa A, Russo S, De Crescenzo A, et al. (Epi)genotype-phenotype correlations in Beckwith-Wiedemann syndrome. Eur J Hum Genet 2016; 24:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brioude F, Lacoste A, Netchine I, et al. Beckwith-Wiedemann syndrome: growth pattern and tumor risk according to molecular mechanism, and guidelines for tumor surveillance. Horm Res Paediatr 2013; 80:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ibrahim A, Kirby G, Hardy C, et al. Methylation analysis and diagnostics of Beckwith-Wiedemann syndrome in 1,000 subjects. Clin Epigenetics 2014; 6:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gazzin A, Carli D, Sirchia F, et al. Phenotype evolution and health issues of adults with Beckwith-Wiedemann syndrome. Am J Med Genet A 2019; 179:1691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slavotinek A, Gaunt L, Donnai D. Paternally inherited duplications of 11p15.5 and Beckwith-Wiedemann syndrome. J Med Genet 1997; 34:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waziri M, Patil SR, Hanson JW, Bartley JA. Abnormality of chromosome 11 in patients with features of Beckwith-Wiedemann syndrome. J Pediatr 1983; 102:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kent L, Bowdin S, Kirby GA, et al. Beckwith Weidemann syndrome: a behavioral phenotype-genotype study. Am J Med Genet B Neuropsychiatr Genet 2008; 147B:1295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott RH, Douglas J, Baskcomb L, et al. Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor. Nat Genet 2008; 40:1329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bliek J, Gicquel C, Maas S, et al. Epigenotyping as a tool for the prediction of tumor risk and tumor type in patients with Beckwith-Wiedemann syndrome (BWS). J Pediatr 2004; 145:796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bliek J, Maas SM, Ruijter JM, et al. Increased tumour risk for BWS patients correlates with aberrant H19 and not KCNQ1OT1 methylation: occurrence of KCNQ1OT1 hypomethylation in familial cases of BWS. Hum Mol Genet 2001; 10:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeBaun MR, Niemitz EL, McNeil DE, et al. Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects. Am J Hum Genet 2002; 70:604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rump P, Zeegers MP, van Essen AJ. Tumor risk in Beckwith-Wiedemann syndrome: A review and meta-analysis. Am J Med Genet A 2005; 136:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weksberg R, Nishikawa J, Caluseriu O, et al. Tumor development in the Beckwith-Wiedemann syndrome is associated with a variety of constitutional molecular 11p15 alterations including imprinting defects of KCNQ1OT1. Hum Mol Genet 2001; 10:2989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duffy KA, Cielo CM, Cohen JL, et al. Characterization of the Beckwith-Wiedemann spectrum: Diagnosis and management. Am J Med Genet C Semin Med Genet 2019; 181:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeBaun MR, Niemitz EL, Feinberg AP. Association of in vitro fertilization with Beckwith-Wiedemann syndrome and epigenetic alterations of LIT1 and H19. Am J Hum Genet 2003; 72:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engel JR, Smallwood A, Harper A, et al. Epigenotype-phenotype correlations in Beckwith-Wiedemann syndrome. J Med Genet 2000; 37:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hatada I, Nabetani A, Morisaki H, et al. New p57KIP2 mutations in Beckwith-Wiedemann syndrome. Hum Genet 1997; 100:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li M, Squire J, Shuman C, et al. Imprinting status of 11p15 genes in Beckwith-Wiedemann syndrome patients with CDKN1C mutations. Genomics 2001; 74:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith AC, Rubin T, Shuman C, et al. New chromosome 11p15 epigenotypes identified in male monozygotic twins with Beckwith-Wiedemann syndrome. Cytogenet Genome Res 2006; 113:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith AC, Shuman C, Chitayat D, et al. Severe presentation of Beckwith-Wiedemann syndrome associated with high levels of constitutional paternal uniparental disomy for chromosome 11p15. Am J Med Genet A 2007; 143A:3010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott RH, Douglas J, Baskcomb L, et al. Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) robustly detects and distinguishes 11p15 abnormalities associated with overgrowth and growth retardation. J Med Genet 2008; 45:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bliek J, Verde G, Callaway J, et al. Hypomethylation at multiple maternally methylated imprinted regions including PLAGL1 and GNAS loci in Beckwith-Wiedemann syndrome. Eur J Hum Genet 2009; 17:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee MP, DeBaun M, Randhawa G, et al. Low frequency of p57KIP2 mutation in Beckwith-Wiedemann syndrome. Am J Hum Genet 1997; 61:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gicquel C, Gaston V, Mandelbaum J, et al. In vitro fertilization may increase the risk of Beckwith-Wiedemann syndrome related to the abnormal imprinting of the KCN1OT gene. Am J Hum Genet 2003; 72:1338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halliday J, Oke K, Breheny S, et al. Beckwith-Wiedemann syndrome and IVF: a case-control study. Am J Hum Genet 2004; 75:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maher ER, Afnan M, Barratt CL. Epigenetic risks related to assisted reproductive technologies: epigenetics, imprinting, ART and icebergs? Hum Reprod 2003; 18:2508.
          </a>
         </li>
         <li class="breakAll">
          Shuman C, Smith AC, Weksberg R. Beckwith-Wiedemann Syndrome. GeneReviews [Internet] 2008.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keren B, Chantot-Bastaraud S, Brioude F, et al. SNP arrays in Beckwith-Wiedemann syndrome: an improved diagnostic strategy. Eur J Med Genet 2013; 56:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russo S, Calzari L, Mussa A, et al. A multi-method approach to the molecular diagnosis of overt and borderline 11p15.5 defects underlying Silver-Russell and Beckwith-Wiedemann syndromes. Clin Epigenetics 2016; 8:23.
          </a>
         </li>
         <li class="breakAll">
          Baskin B, Molecular Genetics Specialist, Pediatric Laboratory Medicine, The Hospital for Sick Children, personal communication, 2010.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eggermann T, Brioude F, Russo S, et al. Prenatal molecular testing for Beckwith-Wiedemann and Silver-Russell syndromes: a challenge for molecular analysis and genetic counseling. Eur J Hum Genet 2016; 24:784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Storm DW, Hirselj DA, Rink B, et al. The prenatal diagnosis of Beckwith-Wiedemann syndrome using ultrasound and magnetic resonance imaging. Urology 2011; 77:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilkins-Haug L, Porter A, Hawley P, Benson CB. Isolated fetal omphalocele, Beckwith-Wiedemann syndrome, and assisted reproductive technologies. Birth Defects Res A Clin Mol Teratol 2009; 85:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Souka AP, Snijders RJ, Novakov A, et al. Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10-14 weeks of gestation. Ultrasound Obstet Gynecol 1998; 11:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griff JR, Duffy KA, Kalish JM. Characterization and Childhood Tumor Risk Assessment of Genetic and Epigenetic Syndromes Associated With Lateralized Overgrowth. Front Pediatr 2020; 8:613260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballock RT, Wiesner GL, Myers MT, Thompson GH. Hemihypertrophy. Concepts and controversies. J Bone Joint Surg Am 1997; 79:1731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leung AK, Fong JH, Leong AG. Hemihypertrophy. J R Soc Promot Health 2002; 122:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones SM, Rahman RS, Bourgeois DJ 3rd, et al. Hemihyperplasia in a 4-month-old. Clin Pediatr (Phila) 2011; 50:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eggermann T, Schönherr N, Meyer E, et al. Epigenetic mutations in 11p15 in Silver-Russell syndrome are restricted to the telomeric imprinting domain. J Med Genet 2006; 43:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inbar-Feigenberg M, Choufani S, Cytrynbaum C, et al. Mosaicism for genome-wide paternal uniparental disomy with features of multiple imprinting disorders: diagnostic and management issues. Am J Med Genet A 2013; 161A:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalish JM, Conlin LK, Bhatti TR, et al. Clinical features of three girls with mosaic genome-wide paternal uniparental isodisomy. Am J Med Genet A 2013; 161A:1929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Postema FAM, Bliek J, van Noesel CJM, et al. Multiple tumors due to mosaic genome-wide paternal uniparental disomy. Pediatr Blood Cancer 2019; 66:e27715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gogiel M, Begemann M, Spengler S, et al. Genome-wide paternal uniparental disomy mosaicism in a woman with Beckwith-Wiedemann syndrome and ovarian steroid cell tumour. Eur J Hum Genet 2013; 21:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beckwith JB. Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations. Am J Med Genet 1998; 79:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valente FM, Sparago A, Freschi A, et al. Transcription alterations of KCNQ1 associated with imprinted methylation defects in the Beckwith-Wiedemann locus. Genet Med 2019; 21:1808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carli D, De Pellegrin M, Franceschi L, et al. Evolution over Time of Leg Length Discrepancy in Patients with Syndromic and Isolated Lateralized Overgrowth. J Pediatr 2021; 234:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimura Y, Kamada Y, Kimura S. Anesthetic management of two cases of Beckwith-Wiedemann syndrome. J Anesth 2008; 22:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomlinson JK, Morse SA, Bernard SP, et al. Long-term outcomes of surgical tongue reduction in Beckwith-Wiedemann syndrome. Plast Reconstr Surg 2007; 119:992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalish JM, Doros L, Helman LJ, et al. Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma. Clin Cancer Res 2017; 23:e115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mussa A, Carli D, Cardaropoli S, et al. Lateralized and Segmental Overgrowth in Children. Cancers (Basel) 2021; 13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cöktü S, Spix C, Kaiser M, et al. Cancer incidence and spectrum among children with genetically confirmed Beckwith-Wiedemann spectrum in Germany: a retrospective cohort study. Br J Cancer 2020; 123:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehrlich PF, Chi YY, Chintagumpala MM, et al. Results of Treatment for Patients With Multicentric or Bilaterally Predisposed Unilateral Wilms Tumor (AREN0534): A report from the Children's Oncology Group. Cancer 2020; 126:3516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katzenstein HM, Langham MR, Malogolowkin MH, et al. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial. Lancet Oncol 2019; 20:719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clericuzio CL, Martin RA. Diagnostic criteria and tumor screening for individuals with isolated hemihyperplasia. Genet Med 2009; 11:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zarate YA, Mena R, Martin LJ, et al. Experience with hemihyperplasia and Beckwith-Wiedemann syndrome surveillance protocol. Am J Med Genet A 2009; 149A:1691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacFarland SP, Mostoufi-Moab S, Zelley K, et al. Management of adrenal masses in patients with Beckwith-Wiedemann syndrome. Pediatr Blood Cancer 2017; 64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mussa A, Duffy KA, Carli D, et al. Defining an optimal time window to screen for hepatoblastoma in children with Beckwith-Wiedemann syndrome. Pediatr Blood Cancer 2019; 66:e27492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Everman DB, Shuman C, Dzolganovski B, et al. Serum alpha-fetoprotein levels in Beckwith-Wiedemann syndrome. J Pediatr 2000; 137:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clericuzio CL, Chen E, McNeil DE, et al. Serum alpha-fetoprotein screening for hepatoblastoma in children with Beckwith-Wiedemann syndrome or isolated hemihyperplasia. J Pediatr 2003; 143:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greer KJ, Kirkpatrick SJ, Weksberg R, Pauli RM. Beckwith-Wiedemann syndrome in adults: observations from one family and recommendations for care. Am J Med Genet A 2008; 146A:1707.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 13555 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19550435" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19550435" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14231762" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : [FAMILIAL MALFORMATION COMPLEX WITH UMBILICAL HERNIA AND MACROGLOSSIA--A "NEW SYNDROME"?].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3770742" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Wiedemann-Beckwith syndrome: presentation of clinical and cytogenetic data on 22 new cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23918458" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Prevalence of Beckwith-Wiedemann syndrome in North West of Italy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12019213" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Discordant KCNQ1OT1 imprinting in sets of monozygotic twins discordant for Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29696471" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Comprehensive meta-analysis reveals association between multiple imprinting disorders and conception by assisted reproductive technology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28634246" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Assisted Reproductive Techniques and Risk of Beckwith-Wiedemann Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28634246" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Assisted Reproductive Techniques and Risk of Beckwith-Wiedemann Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15999116" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Molecular subtypes and phenotypic expression of Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16842655" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Beckwith-Wiedemann syndrome: multiple molecular mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16010676" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12668598" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Beckwith-Wiedemann syndrome demonstrates a role for epigenetic control of normal development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12668598" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Beckwith-Wiedemann syndrome demonstrates a role for epigenetic control of normal development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15372379" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Microdeletion of LIT1 in familial Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15743916" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Microdeletion of target sites for insulator protein CTCF in a chromosome 11p15 imprinting center in Beckwith-Wiedemann syndrome and Wilms' tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15314640" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Microdeletions in the human H19 DMR result in loss of IGF2 imprinting and Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29377879" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome: an international consensus statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24154661" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : High frequency of copy number variations (CNVs) in the chromosome 11p15 region in patients with Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33679886" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Case Report: A Novel Deletion in the 11p15 Region Causing a Familial Beckwith-Wiedemann Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33658067" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A Beckwith-Wiedemann syndrome case with de novo 24 Mb duplication of chromosome 11p15.5p14.3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33541417" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Unusual deletion of the maternal 11p15 allele in Beckwith-Wiedemann syndrome with an impact on both imprinting domains.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10839547" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24916376" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Extensive investigation of the IGF2/H19 imprinting control region reveals novel OCT4/SOX2 binding site defects associated with specific methylation patterns in Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30770769" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Novel familial distal imprinting centre 1 (11p15.5) deletion provides further insights in imprinting regulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10393948" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : A maternally methylated CpG island in KvLQT1 is associated with an antisense paternal transcript and loss of imprinting in Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14627666" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Silencing of CDKN1C (p57KIP2) is associated with hypomethylation at KvDMR1 in Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18571544" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Epigenotype, phenotype, and tumors in patients with isolated hemihyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20933618" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Large de novo deletion of 7p15.1 to 7p12.1 involving the imprinted gene GRB10 associated with a complex phenotype including features of Beckwith Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17994567" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Beckwith-Wiedemann-like macroglossia and 18q23 haploinsufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27235113" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Causes and Consequences of Multi-Locus Imprinting Disturbances in Humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30221575" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Characterization of multi-locus imprinting disturbances and underlying genetic defects in patients with chromosome 11p15.5 related imprinting disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32068234" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Disturbed genomic imprinting and its relevance for human reproduction: causes and clinical consequences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33513760" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Paternal Uniparental Disomy of the Entire Chromosome 20 in a Child with Beckwith-Wiedemann Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27525657" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The subcortical maternal complex: multiple functions for one biological structure?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23385738" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Clinical presentation of 6q24 transient neonatal diabetes mellitus (6q24 TNDM) and genotype-phenotype correlation in an international cohort of patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29574422" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Maternal variants in NLRP and other maternal effect proteins are associated with multilocus imprinting disturbance in offspring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33221824" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Biallelic PADI6 variants cause multilocus imprinting disturbances and miscarriages in the same family.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32928291" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Loss-of-function maternal-effect mutations of PADI6 are associated with familial and sporadic Beckwith-Wiedemann syndrome with multi-locus imprinting disturbance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33583041" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Novel pathogenic variants in NLRP7, NLRP5, and PADI6 in patients with recurrent hydatidiform moles and reproductive failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33583041" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Novel pathogenic variants in NLRP7, NLRP5, and PADI6 in patients with recurrent hydatidiform moles and reproductive failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7820926" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Clinical features and natural history of Beckwith-Wiedemann syndrome: presentation of 74 new cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7541608" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Longitudinal observations on 15 children with Wiedemann-Beckwith syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33687072" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Prenatally diagnosed omphaloceles: Report of 92 cases and association with Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30784096" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Prenatal imaging throughout gestation in Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31670834" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Diagnosis and Management of Placental Mesenchymal Disease. A Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33462953" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Clinical manifestations of placental mesenchymal dysplasia in Japan: A multicenter case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18033734" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The clinical phenotype of mosaicism for genome-wide paternal uniparental disomy: two new reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33810554" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Clinical and Molecular Diagnosis of Beckwith-Wiedemann Syndrome with Single- or Multi-Locus Imprinting Disturbance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2389800" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Apparent postnatal onset of some manifestations of the Wiedemann-Beckwith syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2389800" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Apparent postnatal onset of some manifestations of the Wiedemann-Beckwith syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28475229" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Nomenclature and definition in asymmetric regional body overgrowth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9781907" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Isolated hemihyperplasia (hemihypertrophy): report of a prospective multicenter study of the incidence of neoplasia and review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3044795" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Wiedemann-Beckwith syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3987723" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : The Wiedemann-Beckwith syndrome in four sibs including one with associated congenital hypothyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12584548" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Hypercalciuria in Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10037413" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Renal findings on radiological followup of patients with Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9725306" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Nonmalignant renal disease in pediatric patients with Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20637700" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : A review of the urologic manifestations of Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22015620" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Nephrological findings and genotype-phenotype correlation in Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22585446" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Brain abnormalities in patients with Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16010495" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Beckwith-Wiedemann syndrome: historical, clinicopathological, and etiopathogenetic perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7350313" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Complete and incomplete forms of Beckwith-Wiedemann syndrome: their oncogenic potential.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16925531" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Tumour surveillance in Beckwith-Wiedemann syndrome and hemihyperplasia: a critical review of the evidence and suggested guidelines for local practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Tumours and hemihypertrophy associated with Wiedemann-Beckwith syndrome (Letter to the Editor)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27419809" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Phenotype, cancer risk, and surveillance in Beckwith-Wiedemann syndrome depending on molecular genetic subgroups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28699632" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Wilms tumour in Beckwith-Wiedemann Syndrome and loss of methylation at imprinting centre 2: revisiting tumour surveillance guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25898929" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : (Epi)genotype-phenotype correlations in Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24335096" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Beckwith-Wiedemann syndrome: growth pattern and tumor risk according to molecular mechanism, and guidelines for tumor surveillance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24982696" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Methylation analysis and diagnostics of Beckwith-Wiedemann syndrome in 1,000 subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31339634" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Phenotype evolution and health issues of adults with Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9350814" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Paternally inherited duplications of 11p15.5 and Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6854451" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Abnormality of chromosome 11 in patients with features of Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18314872" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Beckwith Weidemann syndrome: a behavioral phenotype-genotype study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18836444" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15580204" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Epigenotyping as a tool for the prediction of tumor risk and tumor type in patients with Beckwith-Wiedemann syndrome (BWS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11181570" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Increased tumour risk for BWS patients correlates with aberrant H19 and not KCNQ1OT1 methylation: occurrence of KCNQ1OT1 hypomethylation in familial cases of BWS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11813134" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15887271" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Tumor risk in Beckwith-Wiedemann syndrome: A review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11751681" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Tumor development in the Beckwith-Wiedemann syndrome is associated with a variety of constitutional molecular 11p15 alterations including imprinting defects of KCNQ1OT1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31469230" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Characterization of the Beckwith-Wiedemann spectrum: Diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12439823" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Association of in vitro fertilization with Beckwith-Wiedemann syndrome and epigenetic alterations of LIT1 and H19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11106355" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Epigenotype-phenotype correlations in Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9341892" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : New p57KIP2 mutations in Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11414765" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Imprinting status of 11p15 genes in Beckwith-Wiedemann syndrome patients with CDKN1C mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16575195" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : New chromosome 11p15 epigenotypes identified in male monozygotic twins with Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18000906" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Severe presentation of Beckwith-Wiedemann syndrome associated with high levels of constitutional paternal uniparental disomy for chromosome 11p15.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18245390" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) robustly detects and distinguishes 11p15 abnormalities associated with overgrowth and growth retardation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19092779" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Hypomethylation at multiple maternally methylated imprinted regions including PLAGL1 and GNAS loci in Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9311734" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Low frequency of p57KIP2 mutation in Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12772698" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : In vitro fertilization may increase the risk of Beckwith-Wiedemann syndrome related to the abnormal imprinting of the KCN1OT gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15284956" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Beckwith-Wiedemann syndrome and IVF: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14645164" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Epigenetic risks related to assisted reproductive technologies: epigenetics, imprinting, ART and icebergs?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14645164" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Epigenetic risks related to assisted reproductive technologies: epigenetics, imprinting, ART and icebergs?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23892181" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : SNP arrays in Beckwith-Wiedemann syndrome: an improved diagnostic strategy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26933465" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : A multi-method approach to the molecular diagnosis of overt and borderline 11p15.5 defects underlying Silver-Russell and Beckwith-Wiedemann syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26933465" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : A multi-method approach to the molecular diagnosis of overt and borderline 11p15.5 defects underlying Silver-Russell and Beckwith-Wiedemann syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26508573" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Prenatal molecular testing for Beckwith-Wiedemann and Silver-Russell syndromes: a challenge for molecular analysis and genetic counseling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20573391" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : The prenatal diagnosis of Beckwith-Wiedemann syndrome using ultrasound and magnetic resonance imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19107956" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Isolated fetal omphalocele, Beckwith-Wiedemann syndrome, and assisted reproductive technologies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9674084" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10-14 weeks of gestation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33392121" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Characterization and Childhood Tumor Risk Assessment of Genetic and Epigenetic Syndromes Associated With Lateralized Overgrowth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9384434" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Hemihypertrophy. Concepts and controversies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11989139" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Hemihypertrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21339252" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Hemihyperplasia in a 4-month-old.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16236811" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Epigenetic mutations in 11p15 in Silver-Russell syndrome are restricted to the telomeric imprinting domain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23239666" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Mosaicism for genome-wide paternal uniparental disomy with features of multiple imprinting disorders: diagnostic and management issues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23804593" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Clinical features of three girls with mosaic genome-wide paternal uniparental isodisomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30882989" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Multiple tumors due to mosaic genome-wide paternal uniparental disomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23188046" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Genome-wide paternal uniparental disomy mosaicism in a woman with Beckwith-Wiedemann syndrome and ovarian steroid cell tumour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9781906" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30635621" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Transcription alterations of KCNQ1 associated with imprinted methylation defects in the Beckwith-Wiedemann locus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33465347" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Evolution over Time of Leg Length Discrepancy in Patients with Syndromic and Isolated Lateralized Overgrowth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18306025" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Anesthetic management of two cases of Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17312506" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Long-term outcomes of surgical tongue reduction in Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28674120" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34944785" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Lateralized and Segmental Overgrowth in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32451468" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Cancer incidence and spectrum among children with genetically confirmed Beckwith-Wiedemann spectrum in Germany: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32459384" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Results of Treatment for Patients With Multicentric or Bilaterally Predisposed Unilateral Wilms Tumor (AREN0534): A report from the Children's Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30975630" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19367194" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Diagnostic criteria and tumor screening for individuals with isolated hemihyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19610116" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Experience with hemihyperplasia and Beckwith-Wiedemann syndrome surveillance protocol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28066990" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Management of adrenal masses in patients with Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30270492" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Defining an optimal time window to screen for hepatoblastoma in children with Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10891834" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Serum alpha-fetoprotein levels in Beckwith-Wiedemann syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12970646" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Serum alpha-fetoprotein screening for hepatoblastoma in children with Beckwith-Wiedemann syndrome or isolated hemihyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18546283" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Beckwith-Wiedemann syndrome in adults: observations from one family and recommendations for care.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
